Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine

  • E. Cagigal
  • , L. González
  • , R. M. Alonso*
  • , R. M. Jiménez
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)

Abstract

A spectrofluorimetric method has been developed for the determination of two angiotensin II receptor antagonists (ARA II): Losartan and Valsartan. A fractional factorial design and a central composite design were used. The key factors considered in the optimization process were pH, temperature and emission slit width. Maximum fluorescent intensity was established as response for each experiment. The response surfaces confirmed the robustness of the method. A clean-up procedure was used for urine samples that consisted of a solid-phase extraction using C8 cartridges. The total analysis time was lower than 30 min. This method proved to be accurate (RE, 8%), precise (intra- and inter-day coefficients of variation were lower than 8% and sensitive enough (LOQ c.a. 0.5 μg ml-1) to be applied to the determination of Losartan and Valsartan in urine samples.

Original languageEnglish
Pages (from-to)1121-1133
Number of pages13
JournalTalanta
Volume54
Issue number6
DOIs
Publication statusPublished - 6 Jul 2001
Externally publishedYes

Keywords

  • ARA II
  • Experimental design
  • Human urine
  • Spectrofluorimetry

Fingerprint

Dive into the research topics of 'Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine'. Together they form a unique fingerprint.

Cite this